Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;82(7):911-919.
doi: 10.1136/ard-2022-223636. Epub 2023 Mar 3.

Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study

Viking Huss  1   2 , Hannah Bower  3 , Karin Hellgren  3 , Thomas Frisell  3 , Johan Askling  3   2 ; Behalf of the ARTIS group; behalf of the ARTIS group
Collaborators, Affiliations

Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study

Viking Huss et al. Ann Rheum Dis. 2023 Jul.

Abstract

Objective: Assess cancer risks with Janus kinase inhibitors (JAKi) versus biological disease-modifying antirheumatic drugs (bDMARDs) in clinical practice.

Methods: Cohort study of patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) initiating treatment with JAKi, tumour necrosis factor inhibitors (TNFi) or other (non-TNFi) bDMARDs 2016-2020 using prospectively collected data from the Swedish Rheumatology Quality Register linked to other registers including the Cancer Register. We estimated incidence rates, and HRs via Cox regression, for all cancers excluding non-melanoma skin cancer (NMSC), and for individual cancer types including NMSC.

Results: We identified 10 447 patients with RA and 4443 patients with PsA who initiated treatment with JAKi, a non-TNFi bDMARD or a TNFi. Median follow-up times in RA were 1.95, 2.83 and 2.49 years, respectively. In RA, based on 38 incident cancers other than NMSC with JAKi vs 213 with TNFi the overall HR was 0.94 (95% CI 0.65 to 1.38). Based on 59 vs 189 incident NMSC, the HR was 1.39 (95% CI 1.01 to 1.91). At 2 or more years since treatment start, the HR for NMSC was 2.12 (95% CI 1.15 to 3.89). In PsA, based on 5 vs 73 incident cancers other than NMSC, and 8 vs 73 incident NMSC, the corresponding HRs were 1.9 (95% CI 0.7 to 5.2) and 2.1 (95% CI 0.8 to 5.3).

Conclusion: In clinical practice, the short-term risk of cancer other than NMSC in individuals initiating treatment with JAKi is not higher than for TNFi, but we found evidence of increased risk for NMSC.

Keywords: Arthritis, Psoriatic; Arthritis, Rheumatoid; Biological Therapy; Epidemiology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: VH and KH have no competing interests to declare. JA has had or have research agreements with Abbvie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB, mainly in the context of safety monitoring of biologics via ARTIS/Swedish Biologics Register. TF and HB are partly employed by the ARTIS project.

Figures

Figure 1
Figure 1
Hazard ratios with 95% confidence intervals for the outcome all cancers other than non-melanoma skin cancer (overall, and by time since treatment start, number of previous b/tsDMARDs, in a CV enriched population, and using a 90-day latency period) in Swedish patients with RA starting treatment with a JAKi, a TNFi or non-TNFi bDMARD.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337–44. 10.1001/archinte.165.20.2337 - DOI - PubMed
    1. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. . Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308:898–908. 10.1001/2012.jama.10857 - DOI - PubMed
    1. Wu X, Peng H, Wen Y, et al. . Rheumatoid arthritis and risk of lung cancer: meta-analysis and mendelian randomization study. Semin Arthritis Rheum 2021;51:565–75. 10.1016/j.semarthrit.2021.03.015 - DOI - PubMed
    1. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005;32:2130–5. - PubMed
    1. Egeberg A, Thyssen JP, Gislason GH, et al. . Skin cancer in patients with psoriasis. J Eur Acad Dermatol Venereol 2016;30:1349–53. 10.1111/jdv.13619 - DOI - PubMed

Publication types

MeSH terms

Substances